Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Asymmetric Reduction . These insights are designed to support R&D and procurement teams in optimizing their supply chains.
High-purity chiral intermediate via black mold catalysis. Scalable production with significant cost and supply chain advantages for global buyers.
Patent CN110004119B discloses a thermostable epsilon-ketoester reductase mutant enabling efficient synthesis of (R)-alpha-lipoic acid precursors with reduced catalyst loading and enhanced stability.
Patent CN111172124A reveals a novel carbonyl reductase mutant enabling high-concentration synthesis. Discover cost-effective supply chain solutions for this key pharma intermediate.
Industrial process for chiral 2-chloro-1-(2,4-dichlorophenyl) ethyl alcohol. High purity, scalable, cost-effective supply for antifungal API manufacturing.
Discover a safer, scalable preparation method for (3R,5R)-3,5-dihydroxy-6-cyanohexanoate. Enhance supply chain reliability and reduce manufacturing costs with our novel catalytic route.
Patent CN102212041A details a cost-effective synthesis of chiral cyclic beta-amino aryl butyric acid derivatives with high optical purity suitable for pharmaceutical manufacturing.
Advanced Maxacalcitol synthesis via Vitamin D2. Superior yield and stereocontrol for pharmaceutical supply chains. Cost-effective API intermediate manufacturing solutions.
Patent CN102212015A details a cost-effective chiral induction method for high-purity beta-amino acids, offering significant supply chain advantages for API manufacturing.
Patent CN110627673A reveals asymmetric reduction for Formoterol intermediate. Enhances chiral purity and supply chain reliability for pharmaceutical manufacturing.
Patent CN104370755A reveals efficient synthesis for Dolutegravir intermediates. Enables cost reduction and scalable supply chain for global pharmaceutical manufacturers.
Patent CN104232696B enables high ee biocatalysis for pharmaceutical intermediates with significant cost and supply chain advantages for global buyers.
Patent CN104388490A reveals high-yield biocatalytic route. Offers cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing globally.
Novel catalytic route for Crizotinib intermediates. Reduces steps, improves yield, ensures supply chain stability for pharma manufacturing.
Patent CN1778889A details high-purity S-CHBE production via Aureobasidium pullulans. This method offers significant cost reduction and supply chain reliability for global buyers.
Patent CN104651243B details high-yield biocatalytic synthesis of (R)-1,3-butanediol. Offers superior purity and cost-effective supply chain solutions for antibiotic manufacturing.
Novel enzymatic route for (R)-HPBE offers high purity and yield. Reduces cost and supply chain risks for lisinopril intermediate manufacturing globally.
Patent CN105732373A details high-purity (R)-HPBE production via enzymatic reduction. This method offers significant supply chain and cost advantages for pharmaceutical intermediates manufacturing.
Patent CN109749968B reveals a novel Bacillus velezensis strain for synthesizing chiral intermediates. This breakthrough offers significant cost reduction in API manufacturing and superior supply chain reliability.
Patent CN103589665B reveals Rhodococcus qingshengii strain for high-purity (S)-CHBE production. Offers mild conditions and cost reduction in pharmaceutical intermediate manufacturing.
Patent CN108220358A reveals high-yield biocatalytic route for chiral intermediates. Achieve superior purity and supply chain reliability for pharmaceutical manufacturing.